tqb2102
Small moleculeexperimental
Clinical trial activity
13 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
11
Phase 3
4
Phase 4
0
Earliest trial started Feb 28, 2023 (NCT05735496)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2ANTAGONIST
ERBB2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07043725 | Phase 3 | Sep 15, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07136974 | Phase 2 | Sep 1, 2025 | Henan Medical University |
| NCT07008976 | Phase 3 | Jul 7, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT07003074 | Phase 3 | Jun 23, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06798207 | Phase 2 | Mar 31, 2025 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06452706 | Phase 2 | Nov 30, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06767800 | Phase 2 | Nov 21, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06561607 | Phase 3 | Aug 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06496490 | Phase 2 | Aug 6, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06431490 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06198751 | Phase 2 | Feb 5, 2024 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT06115902 | Phase 1 | Nov 17, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
| NCT05735496 | Phase 1 | Feb 28, 2023 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 12 | 12 | 3 | 2023 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1